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INTRODUCTION
Mesenteric ischemia remains a critical
problem with an overall mortality rate as
high as 60% to 80% (1). Intestinal ische-
mia and subsequent reperfusion are en-
countered in a variety of clinical condi-
tions including acute mesenteric
ischemia, intestinal obstruction, incarcer-
ated hernia, small intestine volvulus and
necrotizing colitis. The consequences of
mesenteric ischemia are detrimental to
the patient and usually result in malab-
sorption, severe diarrhea, short bowel
syndrome and death (2). To date, a lim-
ited number of pharmacological agents
have been demonstrated to provide some
benefit in intestinal ischemia and reper-
fusion (I/R) injury conditions; however
none has been entirely successful (2).
I/R is a clinical condition caused by an
initial occlusion of blood supply to a spe-
cific organ, for example, the intestine, and
subsequent tissue injury due to reperfu-
sion and reoxygenation. The restriction of
the arterial blood supply results in tissue
hypoxia leading to cellular damage and
necrosis. The restoration of blood flow
and reoxygenation during reperfusion,
however, is associated with tissue injury
and an exaggerated inflammatory re-
sponse (3–11). A wide array of pathologi-
cal alterations is associated with I/R-in-
duced tissue injury. The initial tissue
hypoxia leads to endothelial cell barrier
dysfunction and a parallel increase in
vascular permeability. The subsequent
reperfusion is associated with cell death
including necrosis and apoptosis and
stimulation of the inflammatory re-
sponses (12–14). In particular, during the
early phase of reperfusion, innate im-
mune cells such as dendritic cells and
monocytes are migrated to the injured tis-
sue to participate in tissue healing (15,16).
However, the recruitment of granulocytes
should be tightly controlled, as accumu-
lation of too many granulocytes promotes
uncontrolled inflammation and tissue in-
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jury. Thus, targeting immune activation is
a promising therapeutic aspect in the
treatment for I/R injury.
AICAR (5-aminoimidazole-4-
 carboxyamide ribonucleoside) is a 
revolutionary cell-permeable compound
that possesses potent antiinflammatory
properties. Recent literature reports that
AICAR could inhibit lipopolysaccharide-
induced expression of proinflammatory
cytokines including tumor necrosis factor
(TNF)-α in several immune cells (17,18).
In animal models, pretreatment with
AICAR attenuated inflammatory re-
sponses in dextran sulfate sodium-
 induced acute and chronic colitis (19). We
therefore hypothesize that AICAR with its
antiinflammatory feature is able to attenu-
ate systemic inflammation and reduce tis-
sue damage after intestinal I/R. In the
current study, we focused on the role of
AICAR in the modulation of inflamma-
tory responses caused by intestinal I/R
and subsequent acute lung injury.
MATERIALS AND METHODS
Experimental Animals
Male Sprague Dawley rats (275 to 325 g),
purchased from Charles River Laborato-
ries (Wilmington, MA, USA) were
housed in a temperature-controlled room
on a 12-h light-to-dark cycle and fed a
standard Purina rat chow diet. All ani-
mal experiments were carried out in ac-
cordance with the Guide for the Care and
Use of Laboratory Animals (20) and were
approved by the Institutional Animal
Care and Use Committee of the Feinstein
Institute for Medical Research.
Animal Model of Intestinal I/R
Rats were fasted for 6 h before surgery.
Intestinal I/R was induced by superior
mesenteric artery (SMA) occlusion as de-
scribed previously by us (21). Briefly, rats
were anesthetized with isoflurane inhala-
tion and a midline laparotomy was per-
formed. The SMA was isolated and
clamped with an atraumatic microvascu-
lar clip for 90 min. After 90-min ischemia,
the SMA clamp was removed to allow
reperfusion. A catheter (PE-50 tubing; BD,
Franklin Lakes, NJ, USA) was inserted
into the femoral vein to administer drugs.
AICAR (30 mg/kg body weight) or vehi-
cle (normal saline) was given IV during a
period of 30 min at the beginning of
reperfusion. Sham animals underwent
the same surgical procedure with the ex-
ception of the SMA clamping or AICAR
administration. At 4 h after treatment or
vehicle administration (that is, 4.5 h after
reperfusion), animals were reanesthetized
and blood was collected via exsanguina-
tion. Afterward, lung tissue and the small
intestine were collected. The left upper
lobe was used for histologic examination
while the lower lobe was used for water-
content determination. The right lung
was snap frozen in liquid nitrogen and
powdered for all other measurements.
Water Content Determination
Lung edema was estimated by com-
paring wet-to-dry weight ratios as de-
scribed previously (21).
Intestinal and Lung Histologic
Examinations
Morphologic changes in the gut and
the lungs were examined by light mi-
croscopy at 4 h after treatment. Briefly,
tissue samples were fixed in 10% forma-
lin in neutral-buffered solution (Sigma-
Aldrich, St. Louis, MO, USA) and paraf-
fin embedded. Tissue blocks were then
sectioned at a thickness of 5 μm, trans-
ferred to glass slides, and stained with
hematoxylin and eosin. The slides were
examined by a light microscope for mor-
phologic assessments. Gut injury was
scored as described previously (11). The
score was based on the following criteria
(score: 0–5): preservation of the villi, ep-
ithelial degeneration/necrosis, erosions
or ulceration and mucin depletion. A
scoring system to grade the degree of
lung injury was used based on previ-
ously described (22) histological features.
The injury was graded as absent, mild,
moderate or severe with a score of 0 to 3
for each feature. A total score of the three
criteria (that is, edema, neutrophil infil-
tration and intraalveolar hemorrhage and
debris) was calculated for each animal.
Granulocyte Myeloperoxidase
Assessment
Myeloperoxidase (MPO) activity was
determined using a method described by
Koike and colleagues (23). Briefly, lung tis-
sues were removed from the euthanized
animal, snap frozen in liquid nitrogen and
stored at –80°C until assay. Frozen tissue
samples were analyzed for MPO activity
measurement as described previously by
us (21). MPO activity (U/g) = A460 × 13.5/g,
where A460 = rate of change in absorbance
between 1 and 3 min.
Determination of Blood and
Pulmonary Levels of TNF-α and IL-6
Blood and lung homogenates were
measured for TNF-α and interleukin
(IL)-6 levels using an enzyme-linked im-
munosorbent assay (ELISA) kit specifi-
cally for rat TNF-α or IL-6 (BD Bio-
sciences, San Jose, CA, USA). The assay
was carried out according to manufac-
turer’s instructions. TNF-α and IL-6 lev-
els were normalized to the protein con-
centration in the sample.
Organ Injury Variables
Serum samples were analyzed for ala-
nine aminotransferase (ALT), aspartate
aminotransferase (AST) and lactate dehy-
drogenase (LDH). Levels were deter-
mined using commercial assay kits ac-
cording to manufacturer’s specifications
(Pointe Scientific, Canton, MI, USA).
Measurement of Bacterial
Translocation
Mesenteric lymph nodes (MLN) were
aseptically removed according to Berg and
Garlington (1979) (24), then weighed and
homogenized in sterile water. Aliquots of
homogenates (1 mL) were plated onto soy
agar with 5% sheep blood (Tripticase
[TSAII]; BD) for bacterial counts. After 48 h
of aerobic incubation at 37°C, the total
number of colonies was identified. The
bacterial count was expressed as colony-
forming units (cfu) per 100 mg of tissue.
Statistical Analysis
All data are expressed as mean ± SE
and compared with one-way ANOVA
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and Student-Newman-Keuls (SNK) test.
Differences in values were considered
significant if p < 0.05.
RESULTS
AICAR Improved Intestinal Integrity
and Reduced Inflammation after
Intestinal I/R
In histological sections, severe mucosal
damage with denudation of villi and col-
lapse of small vessels were observed in
the intestinal tissue after I/R (Figure 1B)
as compared with sham group (Figure 1A).
The structural appearance and the height
of the villi were preserved with AICAR
treatment after intestinal I/R (Figure 1C).
A significant decrease of 46% in the intes-
tinal injury score also was observed with
AICAR treatment (Figure 1D). Intestinal
I/R-associated gut edema also was signif-
icantly reduced with AICAR treatment
(Figure 1E). Intestinal I/R significantly el-
evated serum markers of tissue damage
including ALT (388% increase), AST
(281% increase), LDH (238% increase) and
lactate (177% increase) compared with
sham-operated animals (Figures 2A–D).
Treatment with AICAR decreased ALT,
AST, LDH and lactate levels by 28%,
44%, 41% and 33%, respectively (see Fig-
ures 2A–D). We also investigated
whether the serum levels of the cytokines
TNF-α and IL-6 were affected by the
treatment with AICAR. Intestinal I/R 
significantly increased serum levels of
TNF-α by 595% and IL-6 by 278%, re-
spectively (Figures 3A, B). AICAR admin-
istration dramatically reduced the proin-
flammatory response by 48% and 69%,
respectively (see Figures 3A, B). Thus,
treatment with AICAR immediate to
reperfusion significantly attenuated I/R-
induced multiple organ injury.
AICAR Reduced Bacterial
Translocation into Lymph Nodes after
Intestinal I/R
The intestinal barrier function becomes
compromised after I/R injury. Bacterial
translocation to the mesenteric lymph
node (MLN) was minimal in sham (1.6 ±
0.4 colonies/100 mg lymph nodes) and
extensive in MLN of rats in the vehicle
group subjected to intestinal I/R (104.6 ±
2.3 colonies/100 mg lymph nodes) (Fig-
ure 4). Treatment with AICAR at the be-
ginning of reperfusion significantly re-
duced the bacterial trans location from
the gut to the MLN compared with
 vehicle-treated animals (44.67 ± 4.5
colonies/100 mg lymph nodes) (see Fig-
ure 4).
Figure 1. Alterations in histological appearances of the gut after intestinal I/R. Represen-
tative gut histology (hematoxylin–eosin staining; original magnification 200×) of (A) sham,
(B) vehicle, and (C) AICAR treatment in mice at 4 h after intestinal I/R. (D) The gut dam-
age score and (E) the water content of the gut tissue also are shown. Data are ex-
pressed as mean ± SE and compared by one-way ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle. Scale bar, 100 μm.
Figure 2. Alterations in serum levels of organ injury indicators. (A) ALT, (B) AST, (C) LDH, (D)
lactate in sham-, vehicle- and AICAR-treated mice at 4 h after intestinal I/R. Data are ex-
pressed as mean ± SE and compared by one-way ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle.
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AICAR Attenuated Lung Injury and
Inflammation after Intestinal I/R
Intestinal I/R injury compromises mul-
tiple systems where the lungs among
other organs are commonly affected (25).
In this study, we analyzed lung injury
using three parameters: histologic
changes, neutrophil infiltration (MPO ac-
tivity) and lung edema. While lungs of
sham-operated animals had a normal mi-
croscopic appearance (Figure 5A), the
lung specimens from intestinal I/R vehi-
cle group had substantial changes, includ-
ing alveolar congestion/collapse, hemor-
rhage and inflammatory cell infiltration
(Figure 5B). Histological appearance of
the lungs from AICAR-treated animals
was similar to that of sham animals (Fig-
ure 5C). Lung injury score was increased
significantly at 4 h after intestinal I/R and
vehicle treatment. Administration of
AICAR after gut ischemia significantly re-
duced the lung injury score by 72% (Fig-
ure 5D). In addition, rats subjected to in-
testinal I/R had a significant increase in
lung water content. Lung water content
from AICAR-treated animals was reduced
significantly with no statistical difference
from the sham-operated rats (Figure 5E).
As an indicator of neutrophil infiltration
into the lungs caused by intestinal I/R,
lung CXCL2 mRNA expression and lung
MPO activity were assessed. The lung
CXCL2 mRNA was increased by 188%
after intestinal I/R and treatment with
AICAR decreased it by 82% (Figure 6A).
The lung MPO activity showed a signifi-
cant increase of 241% in the vehicle group
after intestinal I/R as compared with
sham-operated animals and AICAR treat-
ment decreased it by 53% (Figure 6B). To
examine whether AICAR changes tissue
cytokine production, we analyzed the cy-
tokine protein levels in the lungs. Similar
suppressive effects of AICAR could be
found on the lung cytokine levels where
TNF-α and IL-6 increased by 254% and
242% respectively at 4 h after intestinal
I/R with vehicle treatment, while AICAR
treatment decreased tissue TNF-α and
IL-6 levels by 67% and 68% respectively
(Figure 7), which is similar to those in
sham-operated animals. As potential
mechanisms of lung inflammation caused
by intestinal I/R, (iNOS) and COX-2 pro-
tein levels were assessed. The lung iNOS
protein was increased significantly by
300% after intestinal I/R with vehicle
treatment and the treatment with AICAR
reduced it by 70% (Figure 8A). Likewise,
the lung COX-2 protein was increased sig-
nificantly by 211% after intestinal I/R and
Figure 4. Alterations in bacterial transloca-
tion to MLN. MLN homogenates from
sham-, vehicle- and AICAR-treated mice at
4 h after intestinal I/R were plated on soy
agar plates, incubated at 37°C for 48 h,
and the bacterial colonies counted. The
number is shown as colony-forming units
(cfu) per 100 mg tissue. Data are ex-
pressed as mean ± SE and compared by
one-way ANOVA and SNK test. *P < 0.05
versus sham and #P < 0.05 versus vehicle.
Figure 5. Alterations in lung morphology after intestinal I/R. Representative lung histology
(hematoxylin–eosin staining; original magnification 200×) of (A) sham-, (B) vehicle-, (C)
AICAR-treated mice at 4 h after intestinal I/R. The (D) lung damage score calculated as
described in Materials and Methods and (E) lung water content are shown. Data are ex-
pressed as mean ± SE and compared by one-way ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle. Scale bar, 100 μm.
Figure 3. Alterations in serum levels of cy-
tokines. (A) TNF-α and (B) IL-6 in sham-,
vehicle- and AICAR-treated mice at 4 h
after intestinal I/R. Data are expressed as
mean ± SE and compared by one-way
ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle.
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AICAR treatment reduced it by 72% (Fig-
ure 8B).
AICAR Attenuated Apoptosis in the
Lung and in the Intestine after
Intestinal I/R
To determine the effects of AICAR on
apoptosis after intestinal I/R, the lungs
and the intestine were examined in the
sham, vehicle and treatment groups by
terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) staining
(Figures 9A–C). In the vehicle-treated
group, the TUNEL-positive cells in the
lungs were increased significantly (see Fig-
ure 9B) as compared with sham group (see
Figure 9A). Treatment with AICAR signifi-
cantly decreased it by 59% (Figures 9C, D).
DISCUSSION
I/R injury contributes to a wide range
of pathological conditions. Exposure of a
single organ to I/R (for example, the in-
testine), subsequently cause inflamma-
tory activation in other organs (for exam-
ple, the lung), eventually leading to
multiorgan failure. A number of biologi-
cal processes are associated with I/R-
 induced tissue injury. The initial tissue is-
chemia causes impairment in endothelial
barrier function and an increase in vascu-
lar permeability and leakage. However,
I/R leads to, among other things, the acti-
vation of cell death programs, including
apoptosis and necrosis, and stimulation
of the innate and adaptive immune re-
sponses. Therefore, targeting the immune
response is an emerging therapy for the
treatment of I/R injury.
In the current study, we showed that
treatment with AICAR at the beginning of
reperfusion improved histological in-
tegrity of the gut as evidenced by the im-
provement in the morphological appear-
ance and significant decreases in the gut
damage score and the gut water content.
The treatment also attenuated tissue injury
as indicated by decreases in injury indica-
tors and proinflammatory cytokines and a
reduction in bacterial translocation to the
gut. In addition to the gut, treatment with
AICAR after gut I/R maintained lung in-
tegrity, attenuated neutrophil chemotaxis
and infiltration to the lungs and decreased
lung levels of TNF-α and IL-6. Inflamma-
tory mediators such as iNOS and COX-2
were downregulated in the lungs and both
gut and lung apoptosis were attenuated
with AICAR treatment. These data clearly
demonstrated that AICAR ameliorated gut
I/R-associated gut and lung injuries, re-
duced systemic and tissue inflammation
and apoptosis.
The clinical feature of gut ischemia orig-
inates from local and systemic responses
which are induced by impairment in mi-
crocirculation through the activation of
the endothelial cells, monocytes, leuko-
cytes and platelets. Damage to the micro-
circulation leads to intestinal necrosis
and/or systemic inflammatory response
in the whole body or remote organs such
as the lungs. Activated immune cells in
the ischemic gut produce inflammatory
cytokines, TNF-α and IL-6. In this regard,
AICAR treatment significantly decreased
systemic levels of TNF-α and IL-6 possi-
bly released from the ischemic gut or
other remote organs. Gut I/R injury is
one of the most common causes of gut
barrier dysfunction (26). The gastrointesti-
nal tract functions as a site for nutrient
absorption, but it also acts as a barrier 
between the gut and the circulation in
Figure 6. Alterations in lung neutrophil
chemotaxis and infiltration. (A) CXCL2
mRNA expression and (B) MPO in sham-,
vehicle- and AICAR-treated mice at 4 h
after intestinal I/R. Data are expressed as
mean ± SE and compared by one-way
ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle.
Figure 7. Alterations in lung cytokines. (A)
TNF-α, (B) IL-6 in sham-, vehicle- and
AICAR-treated mice at 4 h after intestinal
I/R. Data are expressed as mean ± SE and
compared by one-way ANOVA and SNK
test. *P < 0.05 versus sham and #P < 0.05
versus vehicle.
Figure 8. Alterations in lung inflammatory
mediators. (A) iNOS, (B) COX-2 in sham-,
vehicle- and AICAR-treated mice at 4 h
after intestinal I/R. Data are expressed as
mean ± SE and compared by one-way
ANOVA and SNK test. *P < 0.05 versus
sham and #P < 0.05 versus vehicle.
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preventing noxious substances from en-
tering into the circulation. Maintenance
of the normal epithelial structure and
function is important in preventing trans-
movement of bacteria and other large
molecules. Increased intestinal permeabil-
ity due to gut I/R has been associated
with increased risk of multiple organ fail-
ure and mortality in critically ill patients
(27–29). Our study showed that AICAR
improved gut histological integrity, indi-
cating the important role it had on the
maintenance of the epithelial structure
and function.
The organ injury induced by I/R is not
limited to the ischemic organ. Gut ische-
mia due to transient occlusion of the su-
perior mesenteric artery causes tissue in-
jury locally, and the reperfusion of the gut
leads to heightened inflammatory re-
sponse, thereby causing multiple organ
failure, including acute lung injury. The
systemic inflammatory response after in-
testinal I/R injury activates neutrophils,
which are sequestrated in the pulmonary
microcirculation with the consequent in-
crease of endothelial and epithelial per-
meability, fluid and protein extravasation,
leukocyte sequestration and increases in
pulmonary capillary endothelial cell in-
jury (3,30–33). Our data show that gut I/R
negatively affects lung morphology and
increases MPO, and lung neutrophil
chemotaxis and local cytokine production.
Treatment with AICAR attenuated lung
injury and inflammation. These results are
consistent with previous reports that
AICAR is able to reduce lung injury in a
model of hemorrhagic shock (34). Neu-
trophils play a central role in innate im-
mune and inflammatory responses
(35,36). Although neutrophils eradicate
microbial infections, excessive neutrophil
activation resulting in the release of cy-
tokines and other proinflammatory medi-
ators cause tissue injury and contributes
to multiple organ failure including acute
lung injury (37). Induction of neutropenia
has been shown to diminish severity of
pulmonary injury (38–40). Therefore, it is
possible that the protective effect of
AICAR in gut I/R-associated lung injury
resulted from diminished release of proin-
flammatory mediators from neutrophils.
In the current study, we chose a single
time point of 4 h after reperfusion to de-
termine the effect of AICAR in gut I/R in-
jury. This was based on our previous pub-
lication where we observed significant
increases in organ injury parameters, that
is, AST, ALT, lactate and creatinine at 4 h
after gut I/R injury. In addition, we also
observed significant abnormalities in the
gut and the lungs as evidenced by in-
creases in myeloperoxidase activity and
cytokines levels, that is, TNF-α and IL-6 in
both tissues (41). In the current study, we
observed increases in inflammatory medi-
ators such as iNOS and COX-2 protein
levels and increases in TUNEL-positive
cells in the lungs indicating inflammation
and apoptosis as early as 4 h after gut I/R
injury. Therefore, amelioration of these
early effects systemically and in the gut
and the lungs will be highly effective in
rendering a compound as therapeutic for
gut I/R injury. It is also highly likely that
AICAR administered at the beginning of
reperfusion will be protective from gut
I/R-induced mortality but further experi-
ments are needed for such conclusion.
Our studies also showed that injury in-
dicators, ALT, AST and LDH, are signifi-
cantly attenuated with AICAR treatment
following gut I/R. It is important to rec-
ognize that increases in ALT and AST in
the circulation are indicative of liver dam-
age and that increases in LDH indicates
cellular hypoxia in tissues and as a
marker of common injuries. The attenua-
tion of the injury indicators by AICAR
treatment suggests that AICAR prevents
gut I/R-induced liver damage and other
tissue damage caused by cellular hypoxia.
Antiinflammatory effects of AICAR
have been reported previously. It has
been reported that AICAR treatment re-
duced proinflammatory cytokine produc-
tion and decreased histological alter-
ations associated with inflammation
caused by experimental autoimmune en-
cephalomyelitis and asthma (42,43).
AICAR inhibited release of TNF-α and
Figure 9. Apoptosis in the lung after intestinal I/R. Representative TUNEL staining of lung (A)
sham, (B) vehicle, (C) AICAR-treated mice at 4 h after intestinal I/R. (D) The number of
apoptotic cells in the lung quantified from TUNEL staining. Data are expressed as mean ±
SE and compared by one-way ANOVA and SNK test. *P < 0.05 versus sham and #P < 0.05
versus vehicle.
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IL-6 in LPS-stimulated neutrophils (44).
Moreover, administration of AICAR in
vivo resulted in decreased severity of
LPS-induced lung injury, suggesting that
the antiinflammatory effects of AICAR is
caused by downregulation of the NF-κB
pathway and subsequent decreases in
TNF-α and IL-6 (44). In this regard, our
study showed that AICAR treatment at-
tenuated gut I/R-induced lung levels of
TNF-α and IL-6, suggesting a similar mo-
lecular mechanism of action of AICAR in
gut I/R injury. Inflammatory mediators
such as lung iNOS and COX-2 also were
attenuated with AICAR treatment, indi-
cating a potential role of these factors in
gut I/R-induced lung injury. Impairment
in the lung epithelium and endothelium
barrier function plays a major role in the
development of acute respiratory distress
syndrome, and a key feature of this fail-
ure is the loss of cells through apoptosis
(45). The modulation of apoptosis could
prevent lung fibrosis, and the progression
into acute lung injury (24,45–47). AICAR
attenuated lung apoptosis in gut I/R-as-
sociated lung injury as indicated by the
reduction of apoptotic cells in the lung
parenchyma after treatment. In addition
to the lung, AICAR treatment also signifi-
cantly reduced gut apoptosis.
Although the precise mechanism by
which AICAR exerts anti-inflammation
in gut I/R injury is not yet clear, AICAR
has been shown to have an antiinflam-
matory effect through inhibition of LPS-
induced proinflammatory mediators in-
cluding TNF-α, IL-1β and IL-6 (17). It
has been suggested that the antiinflam-
matory effects of AICAR could be medi-
ated by systemic changes. LPS stimula-
tion elevates CD14 expression and
pretreatment with AICAR significantly
suppressed these elevations (48). LPS
stimulation decreases AMPK activity in
macrophages, and AICAR upregulates
its activity and inhibits cytokine produc-
tion (49). AICAR inhibits NF-κB signal-
ing through AMPK activation, indicating
a direct effect of AICAR (48). AICAR is a
pharmacological activator of AMPK (50).
Some reports have shown that the effects
of AICAR are independent of AMPK ac-
tivation (18,51–53). We have not ana-
lyzed AMPK activation in gut I/R injury.
It is possible that the protective effect of
AICAR in gut I/R injury is mediated by
either AMPK independent or dependent
action of AICAR or both. Future studies
are warranted for such hypothesis.
It is not known whether AICAR acts di-
rectly on the leukocytes, endothelial cells
and/or epithelial cells to facilitate protec-
tion in gut I/R injury. However, it has
been reported that AMPK activation with
AICAR attenuated LPS-induced endothe-
lial hyperpermeability in vitro and that
pretreatment with AICAR reduced LPS-
induced lung injury and endothelial hy-
perpermeability by activation of the
Rac/Cdc42/PAK pathway by AMPK acti-
vation (54). Furthermore, activation of
AMPK attenuated endothelial cell apopto-
sis by increasing the expression of anti-
apoptotic proteins Bcl-2 and survivin (55).
In another study, upregulation of AMPK
by the cystic fibrosis transmembrane con-
ductance regulator in cystic fibrosis miti-
gates excessive inflammation in airway
epithelial cells (56). Activation of AMPK
by AICAR is involved in the regulation of
creatine transporter in kidney epithelial
cells (57). A recent study showed that acti-
vation of AMPK by AICAR enhanced
neutrophil chemotaxis and improved
phagocytosis and bacterial killing in vitro
(58). Thus, there are a myriad of reports
available on the molecular mechanism of
AMPK activation by AICAR in different
cell types, including endothelial cells, ep-
ithelial cells and neutrophils. Further
studies are needed to examine the exact
mechanism of AICAR in gut I/R injury.
Intestinal I/R is encountered in diverse
clinical conditions and its consequences
are devastating to the patient, eventually
leading to death. Ischemia to a specific
organ often leads to injuries in other or-
gans and causes multiple organ failure. In
this study, a transient occlusion of the su-
perior mesenteric artery caused signifi-
cant damages to the gut as well as the
lung. AICAR improved gut integrity, re-
duced bacterial translocation and sys-
temic levels of inflammatory cytokines,
TNF-α and IL-6. Activated neutrophil mi-
gration into the lungs is a key component
of the progression of acute lung injury.
Intestinal I/R led to neutrophil migration
into the lungs as evidenced by increases
in MPO, neutrophil chemotaxis and local
cytokine production. AICAR treatment
attenuated lung injury and inflammation.
In summary, AICAR treatment in intes-
tinal I/R protected the ischemic organ as
well as the lung. These data indicate that
AICAR can be developed as a novel ther-
apeutic for intestinal I/R and subsequent
acute lung injury.
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